---
title: "Ionis Pharmaceuticals tumbles 9% as Phase 3 trial misses primary endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292338837.md"
description: "Ionis shares drop 9% after Phase 3 CARDIO-TTRansform trial fails primary endpoint; law firms launch securities probes."
datetime: "2026-07-10T15:31:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292338837.md)
  - [en](https://longbridge.com/en/news/292338837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292338837.md)
---

# Ionis Pharmaceuticals tumbles 9% as Phase 3 trial misses primary endpoint

Ionis 制药 (IONS.US) 盘中跌**9.00%**，现报**58.485 美元**。

跌幅扩大源于 Phase 3 CARDIO-TTRansform 试验未达减少心血管死亡率及复发事件的主要终点。尽管药物在单药治疗亚组中显示风险降低，但整体结果令市场失望。

SueWallSt 与 Levi & Korsinsky 两家律所已于 7 月 10 日通知投资者，正就潜在证券法违规行为展开调查，焦点在于 CEO 此前关于试验成功的声明是否构成重大误导。

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Ionis Q2 adjusted operating loss narrows](https://longbridge.com/en/news/294198021.md)
- [Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/293897817.md)
- [Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by California Public Employees Retirement System](https://longbridge.com/en/news/293717941.md)
- [Ionis announces Dr. Frank Bennett, chief scientific officer, to retire | IONS Stock News](https://longbridge.com/en/news/294199095.md)
- [Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/294341144.md)